Table 1: Clinicopathologic variables.

Variable

Outcome (n = 54)

Age at diagnosis, years (median; range)

48 (29-79)

Tumor size prior to treatment, cm (median; range)

2.9 (0-13)

Tumor size post treatment, cm (median; range)

0.3 (0-9.9)

Pre-treatment MRI

Negative nodes

Positive (enlarged/suspicious/abnormal) nodes

 

6 (11.1%)

48 (88.9%)

Post-treatment MRI

Negative nodes

Positive (enlarged/suspicious/abnormal) nodes

 

51 (94.4%)

3 (5.6%)

Pre-treatment Axillary Biopsy

None

Negative

Positive

 

13 (24.1%)

7 (13.0%)

34 (62.9%)

Pre-treatment Stage

I

II

III

 

2 (3.7%)

30 (55.6%)

22 (40.7%)

Final Pathology Stage

No residual carcinoma

0

I

II

III

 

18 (33.3%)

6 (11.1%)

8 (14.8%)

13 (24.1%)

9 (16.7%)

Breast surgery

Breast conserving surgery

Mastectomy

 

17 (31.5%)

37 (68.5%)

Axillary surgery

SLND

SLND + ALND

ALND

 

13 (24.1%)

15 (27.8%)

26 (48.1%)

Receptor status

ER+/PR+/HER2-

ER+/PR+/HER2+

ER-/PR-/HER2+

ER-/PR-/HER2-

 

11 (23.9%)

8 (17.4%)

15 (32.6%)

12 (26.1%)

Radiologic complete response (rCR) for breast only

13 (24.1%)

Receptor status of patients with rCR for breast only

ER+/PR+/HER2-

ER+/PR+/HER2+

ER-/PR-/HER2+

ER-/PR-/HER2-

 

1 (8.3%)

4 (33.3%)

5 (41.7%)

2 (16.7%)

Radiologic complete response (rCR) for breast & axilla

10 (18.5%)

Receptor status of patients with rCR for breast & axilla

ER+/PR+/HER2-

ER+/PR+/HER2+

ER-/PR-/HER2+

ER-/PR-/HER2-

 

0 (0.0%)

3 (30.0%)

5 (50.0%)

2 (20.0%)

Pathologic complete response (pCR)

18 (33.3%)

Receptor status of patients with pCR

ER+/PR+/HER2-

ER+/PR+/HER2+

ER-/PR-/HER2+

ER-/PR-/HER2-

 

1 (5.9%)

4 (23.5%)

8 (47.1%)

4 (23.5%)